866-997-4948(US-Canada Toll Free)

Fallopian Tube Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 158 Pages


Global Markets Directs, \'Fallopian Tube Cancer - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. 

Fallopian Tube Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Fallopian Tube Cancer.
  • A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fallopian Tube Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Fallopian Tube Cancer 9
Fallopian Tube Cancer Therapeutics under Development by Companies 11
Fallopian Tube Cancer Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Fallopian Tube Cancer Therapeutics - Products under Development by Companies 20
Fallopian Tube Cancer Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Fallopian Tube Cancer Therapeutics Development 24
Boehringer Ingelheim GmbH 24
Kyowa Hakko Kirin Co., Ltd. 25
Amgen Inc. 26
Sanofi-Aventis 27
Eli Lilly and Company 28
Oxford BioMedica plc 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Cell Therapeutics, Inc. 32
EntreMed, Inc. 33
Marshall Edwards, Inc. 34
Oncolytics Biotech Inc. 35
Array BioPharma Inc. 36
Synta Pharmaceuticals Corp. 37
Spectrum Pharmaceuticals, Inc. 38
Viral Genetics, Inc. 39
ImmunoVaccine Technologies Inc. 40
TRACON Pharmaceuticals, Inc. 41
RECEPTA Biopharma S.A. 42
Kyowa Hakko Kirin Pharma, Inc. 43
Fallopian Tube Cancer - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 51
trebananib - Drug Profile 51
alisertib - Drug Profile 53
paclitaxel poliglumex - Drug Profile 55
ENMD-2076 - Drug Profile 59
elesclomol - Drug Profile 61
TroVax - Drug Profile 63
ramucirumab - Drug Profile 65
MEK-162 - Drug Profile 69
vatalanib + [docetaxel] - Drug Profile 72
erlotinib hydrochloride + [bevacizumab] + [carboplatin] + [paclitaxel] - Drug Profile 73
bendamustine hydrochloride - Drug Profile 75
idronoxil + [carboplatin] - Drug Profile 76
Docetaxel + Yondelis + Pegfilgrastim - Drug Profile 78
docetaxel + [trabectedin] + pegfilgrastim - Drug Profile 80
ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine + [sargramostim] - Drug Profile 81
trebananib + [doxorubicin liposomal] - Drug Profile 83
Taxotere + Eloxatin + Avastin - Drug Profile 85
TRC-105 - Drug Profile 87
Monoclonal antibody hu3S193 - Anti-LeY - Drug Profile 89
erlotinib hydrochloride + [bevacizumab] - Drug Profile 90
EGEN-001 - Drug Profile 92
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 94
everolimus + [bevacizumab] - Drug Profile 96
OCDC Dendritic Cell Vaccine - Drug Profile 98
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 99
bevacizumab + [irinotecan hydrochloride] - Drug Profile 100
Reolysin + [paclitaxel] - Drug Profile 101
NY-ESO-1 Overlapping Peptides Vaccine - Drug Profile 103
Belotecan + Etoposide - Drug Profile 104
SJG-136 - Drug Profile 105
belinostat + [carboplatin] - Drug Profile 106
Docetaxel + Yondelis + Filgrastim - Drug Profile 107
vandetanib + [docetaxel] - Drug Profile 109
trebananib + [carboplatin] + [paclitaxel] - Drug Profile 110
KHK-2866 + [carboplatin] + [gemcitabine hydrochloride] - Drug Profile 112
KHK-2866 + [paclitaxel] - Drug Profile 114
KHK-2866 + [doxorubicin] 116
- Drug Profile 116
KHK-2866 - Drug Profile 118
nintedanib + [carboplatin] + [doxorubicin] - Drug Profile 119
ABT-767 - Drug Profile 121
Globo-H-GM2-sTn-TF-Tn-KLH Conjugate - Drug Profile 122
pazopanib hydrochloride + [carboplatin] + [paclitaxel] - Drug Profile 123
pazopanib hydrochloride + [paclitaxel] - Drug Profile 125
dalantercept - Drug Profile 126
hydroxychloroquine + sorafenib - Drug Profile 127
Pralatrexate + Carboplatin - Drug Profile 128
Fallopian Tube Cancer Therapeutics - Drug Profile Updates 129
Fallopian Tube Cancer Therapeutics - Discontinued Products 142
Fallopian Tube Cancer Therapeutics - Dormant Products 143
Fallopian Tube Cancer - Product Development Milestones 146
Featured News & Press Releases 146

Appendix 154
Methodology 154
Coverage 154
Secondary Research 154
Primary Research 154
Expert Panel Validation 154
Contact Us 155
Disclaimer 155

List of Table


Number of Products Under Development for Fallopian Tube Cancer, H1 2013 12
Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 19
Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26
Boehringer Ingelheim GmbH, H1 2013 27
Kyowa Hakko Kirin Co., Ltd., H1 2013 28
Amgen Inc., H1 2013 29
Sanofi-Aventis, H1 2013 30
Eli Lilly and Company, H1 2013 31
Oxford BioMedica plc, H1 2013 32
Millennium Pharmaceuticals, Inc., H1 2013 33
Novartis AG, H1 2013 34
Cell Therapeutics, Inc., H1 2013 35
EntreMed, Inc., H1 2013 36
Marshall Edwards, Inc., H1 2013 37
Oncolytics Biotech Inc., H1 2013 38
Array BioPharma Inc., H1 2013 39
Synta Pharmaceuticals Corp., H1 2013 40
Spectrum Pharmaceuticals, Inc., H1 2013 41
Viral Genetics, Inc., H1 2013 42
ImmunoVaccine Technologies Inc., H1 2013 43
TRACON Pharmaceuticals, Inc., H1 2013 44
RECEPTA Biopharma S.A., H1 2013 45
Kyowa Hakko Kirin Pharma, Inc., H1 2013 46
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Stage and Molecule Type, H1 2013 53
Fallopian Tube Cancer Therapeutics - Drug Profile Updates 132
Fallopian Tube Cancer Therapeutics - Discontinued Products 145
Fallopian Tube Cancer Therapeutics - Dormant Products 146
Fallopian Tube Cancer Therapeutics - Dormant Products (Contd..1) 147
Fallopian Tube Cancer Therapeutics - Dormant Products (Contd..2) 148

List of Chart


Number of Products under Development for Fallopian Tube Cancer, H1 2013 12
Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Route of Administration, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Molecule Type, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *